Related Experiment Video
Updated: Jul 14, 2026
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
FLT3 as a therapeutic target in childhood acute leukemia
Matthew C Stubbs1, Scott A Armstrong
1Division of Hematology/Oncology, Children's Hospital, Department of Pediatric Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA.
Abstract:
During the past few years, a major focus of leukemia research has centered on tyrosine kinases as potential therapeutic targets. This is due in large part to the success of imatinib mesylate (STI571, Gleevec), which has proven effective as a therapy for chronic myeloid leukemias bearing the t(9;22) encoding the BCR-ABL kinase. It has become increasingly evident that mutations producing constitutively active tyrosine kinases play a role in leukemogenesis. Another kinase that has drawn significant attention is the FMS-like tyrosine kinase 3 (FLT3). FLT3 is expressed in most childhood acute leukemias. Select genetic subgroups possess particularly high-level expression, with a significant percentage therein harboring activating mutations. In this review we will discuss FLT3 as a potential therapeutic target in childhood acute leukemias. We will highlight the role of FLT3 in hematopoiesis, and how when activated, it may play a role in the development of acute myeloid or acute lymphoblastic leukemia. We will examine the successes in elucidating FLT3 function in acute leukemias, highlight current FLT3 targeted therapeutics, and discuss how FLT3 inhibitors might be used in combination therapies in the future.
Insights
FMS-like tyrosine kinase 3 (FLT3) is a promising therapeutic target in childhood acute leukemias. Activating mutations in FLT3 contribute to leukemogenesis, and FLT3 inhibitors show potential for combination therapies.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Tyrosine kinases are key targets in leukemia research, exemplified by imatinib mesylate's success in chronic myeloid leukemia.
- Activating mutations in tyrosine kinases, including FMS-like tyrosine kinase 3 (FLT3), are implicated in leukemogenesis.
- FLT3 is frequently expressed in childhood acute leukemias, with activating mutations found in a significant subset.
Purpose of the Study:
- To review FMS-like tyrosine kinase 3 (FLT3) as a potential therapeutic target in childhood acute leukemias.
- To elucidate the role of FLT3 in normal hematopoiesis and its aberrant activation in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
- To examine current FLT3-targeted therapeutics and explore their potential in future combination therapies.
Main Methods:
- Literature review focusing on the role of FLT3 in hematopoiesis and leukemogenesis.
- Analysis of genetic subgroups with high FLT3 expression and activating mutations.
- Examination of current FLT3-targeted therapies and their clinical implications.
Main Results:
- FLT3 plays a critical role in hematopoiesis, and its aberrant activation contributes to the development of AML and ALL.
- Specific genetic subgroups of childhood acute leukemias exhibit high FLT3 expression and activating mutations.
- FLT3 inhibitors represent a developing class of targeted therapeutics for acute leukemias.
Conclusions:
- FLT3 is a significant therapeutic target for childhood acute leukemias due to its role in leukemogenesis.
- Targeted inhibition of FLT3 holds promise for treating specific genetic subgroups of acute leukemias.
- Future research should focus on optimizing FLT3 inhibitor efficacy, potentially through combination therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...